These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 11207051)

  • 21. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
    Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
    J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
    Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
    Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
    Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
    Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
    Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
    Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast.
    Meijnen P; Oldenburg HS; Peterse JL; Bartelink H; Rutgers EJ
    Ann Surg Oncol; 2008 Jan; 15(1):235-43. PubMed ID: 17987342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
    Sakorafas GH; Tsiotou AG
    Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
    Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
    Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.
    Kreike B; Halfwerk H; Kristel P; Glas A; Peterse H; Bartelink H; van de Vijver MJ
    Clin Cancer Res; 2006 Oct; 12(19):5705-12. PubMed ID: 17020974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Millar EK; Tran K; Marr P; Graham PH
    Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.